Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study

NCT05954910 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05954910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05954910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Active, not recruiting
Start date
August 25, 2023
Completion date
May 31, 2027
Enrollment
1,000 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma